Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
Michiel S. Van Der Heijden, Matthew D. Galsky, Ricky S. Joshi, James W.F. Catto et autres
636 Background: In NIAGARA (NCT03732677), addition of perioperative D to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) demonstrated a significant improvement in event-free survival (EFS) and overall survival and a numerical increase in pathological complete response (pCR) vs NAC and RC alone …
nl, us, es, gb, jp, it, vn, ru, ca (code pays fourni par la source)
7 citations
Journal of Clinical Oncology